Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease

Ophthalmic Plastic and Reconstructive Surgery

Volumn 30, Issue 5, 2014, Pages 415-419

  Ayabe, Reed ^a   Rootman, Dan B ^b   Hwang, Catherine J ^b   Ben Artzi, Ami ^c   Goldberg, Robert ^b  

^a JULES STEIN EYE INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTITHYROID AGENT; RADIOACTIVE IODINE; STEROID; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABLATION THERAPY; ADULT; AGED; BINOCULAR VISION; CHEMOSIS; CLINICAL ARTICLE; DIARRHEA; DIPLOPIA; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYE PAIN; EYE SWELLING; EYELID EDEMA; EYELID ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFUSION RELATED REACTION; MALE; MIDDLE AGED; NERVE FUNCTION; OPTIC NERVE; PATIENT HISTORY OF THYROIDECTOMY; RETROSPECTIVE STUDY; REVIEW; SEPSIS; STEROID THERAPY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; EYE MOVEMENT; GRAVES OPHTHALMOPATHY; ORBITAL CELLULITIS; ORBITAL MYOSITIS; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VISUAL FIELD;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; EYE MOVEMENTS; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OPTIC NERVE; ORBITAL CELLULITIS; ORBITAL MYOSITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VISUAL ACUITY; VISUAL FIELDS;

EID: 84914703821     PISSN: 07409303     EISSN: 15372677     Source Type: Journal    
DOI: 10.1097/IOP.0000000000000211     Document Type: Review

References (15)

1. Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011;96:320-32.
2. Bartalena L, Krassas GE, Wiersinga W, et al.; European Group on Graves' Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab 2012;97:4454-63.
3. Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy. J Clin Endocrinol Metab 2003;88:4246-50.
4. Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005;24:117-9.
5. Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond) 2005;19:1286-9.
6. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
7. Greenberg JD, Reed G, Decktor D, et al.; CORRONA Investigators. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42.
8. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34.
9. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
10. Galloway JB, Hyrich KL, Mercer LK, et al.; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31.
11. van Steensel L, van Hagen PM, Paridaens D, et al. Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy. Br J Ophthalmol 2011;95:735-8.
12. Mourits M P, Prummel M F, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47:9-14.
13. Moleti M, Mattina F, Salamone I, et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy. Thyroid 2003;13: 653-8.
14. Leo M, Marcocci C, Pinchera A, et al. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 2012;97:E44-8.
15. Zang S, Ponto KA, Pitz S, et al. Dose of intravenous steroids and therapy outcome in Graves' orbitopathy. J Endocrinol Invest 2011;34:876-80.